Literature DB >> 24371403

Lichenoid drug eruption after low-dose imatinib mesylate treatment.

Jae-Hyung Lee1, Jong-Yoon Chung1, Mi-Young Jung1, Cho Rok Kim1, Ji-Ho Park1, Ji-Hye Park2, Jong-Hee Lee1, Joo-Heung Lee1, Jun-Mo Yang1, Dong-Youn Lee1.   

Abstract

Entities:  

Year:  2013        PMID： 24371403      PMCID： PMC3870224          DOI： 10.5021/ad.2013.25.4.500

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN： 1013-9087            Impact factor:   1.444


× No keyword cloud information.
  4 in total

1.  Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect.

Authors:  J Dalmau; L Peramiquel; L Puig; M T Fernández-Figueras; E Roé; A Alomar
Journal:  Br J Dermatol       Date:  2006-06       Impact factor: 9.302

2.  Cutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia.

Authors:  Tamihiro Kawakami; Takeshi Kawanabe; Yoshinao Soma
Journal:  Acta Derm Venereol       Date:  2009       Impact factor: 4.437

3.  Dose-dependent severe cutaneous reactions to imatinib.

Authors:  S Ugurel; R Hildenbrand; E Dippel; A Hochhaus; D Schadendorf
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

Review 4.  Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib.

Authors:  Iris Amitay-Laish; Salomon M Stemmer; Mario E Lacouture
Journal:  Dermatol Ther       Date:  2011 Jul-Aug       Impact factor: 2.851
  4 in total
  2 in total

1.  Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib.

Authors:  Min Kyung Lee; Won Joo Kwon; Eun Byul Cho; Eun Joo Park; Kwang Ho Kim; Kwang Joong Kim
Journal:  Ann Dermatol       Date:  2015-10-02       Impact factor: 1.444

2.  Oral and cutaneous lichenoid eruption with nail changes due to imatinib treatment in a chinese patient with chronic myeloid leukemia.

Authors:  Jiang An Zhang; Jian Bin Yu; Xiao Hong Li; Lei Zhao
Journal:  Ann Dermatol       Date:  2015-03-24       Impact factor: 1.444
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.